Aesther Healthcare Acquisition Corp. Warrant (OCEAW)
Market Open
10 Feb, 21:00
OTC PINK OTC PINK Primary $
0. 03
+0.03
+1,762.5%
$
20.4M Market Cap
- P/E Ratio
- Div Yield
184,700 Volume
- Eps
$ 0
Previous Close Want to track OCEAW and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
OCEAW trading today higher at $0.03, an increase of 1,762.5% from yesterday's close, completing a monthly increase of 0% or $0.03. Over the past 12 months, OCEAW stock gained 1,762.5%.
OCEAW is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
OCEAW Chart
Aesther Healthcare Acquisition Corp. Warrant (OCEAW) FAQ
What is the stock price today?
The current price is $0.03.
On which exchange is it traded?
Aesther Healthcare Acquisition Corp. Warrant is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is OCEAW.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 20.4M.
Has Aesther Healthcare Acquisition Corp. Warrant ever had a stock split?
No, there has never been a stock split.
Aesther Healthcare Acquisition Corp. Warrant Profile
| Financial Services Industry | Financials Sector | M. Michelle Berrey CEO | OTC PINK Exchange | 67644C112 CUSIP |
| US Country | 7 Employees | - Last Dividend | - Last Split | - IPO Date |
Ocean Biomedical, Inc. is a biopharmaceutical enterprise primarily engaged in identifying and advancing novel therapeutic agents. Their research and development efforts span several key disease areas, including cancer, fibrotic conditions, infectious illnesses, and inflammatory disorders. The company's current development pipeline features both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are engineered to target Chi3l1 and are being investigated for treating non-small cell lung cancer and glioblastoma multiforme, a type of brain tumor. Furthermore, Ocean Biomedical is progressing a small molecule therapeutic designed to interact with Chit1, intended for individuals afflicted with Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Their proprietary WPDS platform has generated three additional product candidates: a vaccine aimed at preventing malaria; a humanized monoclonal antibody treatment; and a small molecule treatment, with both malaria therapeutics specifically targeting the Plasmodium falciparum glutamic-acid-rich protein (PfGARP). The company is also developing a therapy for hospitalized patients suffering from COVID-19. Founded in 2019, Ocean Biomedical's operations are headquartered in Providence, Rhode Island.
Contact Information
Address: Room 325, 55 Claverick Street
Phone: 401-444-7375
Website: http://www.oceanbiomedical.com
